China clamps down on investigator-initiated clinical trials, tightening oversight

China has announced tighter oversight of investigator-initiated trials (ITTs), requiring these studies to obtain approval from the National Medical Products Administration before they can begin. The move replaces the previous system that let researchers launch trials without formal sign-off.

ITTs have been a key driver of China’s rapid biomedical growth, allowing faster translation of research, greater physician participation, and contributing billions in sales from newly approved drugs. They helped the country surpass the United States in research spending, patent filings and the number of clinical trials.

The new regulations fine-tune the ITT framework and are expected to affect Chinese investigators and some U.S. collaborators who rely on the more flexible approach. Officials say the changes aim to improve safety and data quality.

The shift arrives as U.S. policymakers explore ways to speed their own trial processes, highlighting a trade-off between speed and regulatory rigor.